Trial Profile

A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Lurbinectedin (Primary)
Indications Bladder cancer; Carcinoma; Neuroendocrine tumours; Renal cancer; Ureteral neoplasms; Urethral cancer
Focus Therapeutic Use
Acronyms LASER

Most Recent Events

19 Dec 2024 Planned number of patients changed from 35 to 45.
19 Jun 2024 Planned initiation date (estimated date of recruitment of the first subject) changed to 13 Jun 2024.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com